Pharma News

The National Pharmaceutical Pricing Authority (NPPA) has fixed the retail prices of 37 new drug formulations under the Drugs (Prices Control) Order (DPCO), 2013, through an order issued on December 24, 2025. The decision, published in the Gazette of India, aims to regulate the prices of commonly used medicines across therapeutic segments, while ensuring affordability and transparency for consumers.

Johnson & Johnson has officially completed its acquisition of Halda Therapeutics OpCo, Inc., a clinical-stage biotechnology company known for its innovative cancer-targeting technology, in a deal valued at USD 3.05 billion in cash.

A recent study published in Engineering has shed light on the potential therapeutic effects of dihydrotanshinone I (DHT), a compound derived from the traditional Chinese herb Salvia miltiorrhiza, on ovarian cancer. The research, conducted by a team from Zhejiang Chinese Medical University and Jiangsu Normal University, reveals that DHT can induce autophagic cell death in ovarian cancer cells by disrupting the sortilin 1 (SORT1)-mediated autophagy–lysosome pathway.

Dr. Ruchi Sogarwal, a distinguished leader in public health and corporate affairs, Takeda Pharma, has been honoured with the Rajasthan WGA Award for Leadership in Corporates and recognised among the Top 10 Women Leaders in Business & Corporates. The award celebrates Rajasthan ki beti who have successfully broken barriers to reach leadership positions in national and global corporate leadership tables, inspiring the next generation of women leaders.

Bioeq AG, a Swiss biopharmaceutical company, and Zydus Lifesciences Limited , an innovation-led life-sciences company with an international presence, today announced that its wholly owned subsidiary, Zydus Lifesciences Global FZE, United Arab Emirates has entered into a strategic partnership with Bioeq, for the licensing, supply and commercialization of Bioeq`s Vascular Endothelial Growth Factor (VEGF) inhibitor NUFYMCO®, an interchangeable biosimilar of Lucentis®1 (Ranibizumab) for the U.S. market. The Biologics License Application (BLA) for NUFYMCO® has been approved by U.S.